WHO prequalifies first malaria treatment designed for newborns and young infants
The Facts
- WHO announced the prequalification of artemether-lumefantrine as the first malaria treatment specifically designed for newborns and young infants.
- The infant formulation is intended for babies weighing roughly 2 to 5 kilograms.
- Before this prequalification, infants with malaria were generally treated with formulations intended for older children.
- Multiple reports say using older-child formulations in infants carried risks including dosing errors, side effects, and toxicity.
- WHO said prequalification means the medicine meets international standards for quality, safety, and efficacy.
- WHO and several reports said the prequalification is expected to help expand access to quality-assured treatment for an underserved patient group.
- The development matters most for infants in malaria-endemic regions, with several reports highlighting Africa as a major affected region.
- Some reports said WHO announced the infant treatment alongside the prequalification of additional rapid diagnostic tests, indicating broader malaria-control efforts are continuing beyond treatment access.
Context
What does WHO prequalification mean here?
WHO said its prequalification designation means the medicine meets international standards of quality, safety and efficacy; one report also notes that this status can enable procurement by UN agencies and other public-sector buyers NDTV,News Directory 3.
Why was a separate infant malaria treatment needed?
Reports say newborns and small infants had been treated with formulations made for older children, which increased the risk of incorrect dosing, side effects and toxicity. The new formulation is designed specifically for that younger, lower-weight group SCMP,KBC | Kenya's Watch…,Healthwise.
Who is most affected by this change?
The treatment is aimed at newborns and young infants weighing about 2 to 5 kilograms, particularly in malaria-endemic regions. Several reports point to Africa as a major focus because many infants there are born in areas where malaria remains common UrduPoint,Latest Nigeria News…,see.news.
How left and right read it
What stands out is a concrete fix for a vulnerable group that had been underserved. Newborns and young infants had generally been treated with medicines intended for older children, despite reported risks of dosing errors, side effects, and toxicity; WHO says this prequalified formulation meets international standards and should help expand access where malaria hits hardest.
The key point is that this is a targeted, standards-based approval rather than a vague promise. WHO says the infant treatment meets international standards for quality, safety, and efficacy, and it is designed for babies weighing roughly 2 to 5 kilograms; paired with additional prequalified rapid diagnostic tests, it suggests malaria-control efforts are being built around practical tools that can be deployed.
The receipts — all 22 sources
Wire services (1)
Independent coverage (21)
Facts first. Then every angle.
The day’s biggest stories in one short brief — the facts everyone agrees on, then the competing values behind the headlines. Free in your inbox.